biosimilar

  1. P

    Ranluspec Approval: Lupin's Biosimilar for Eye Conditions Gains EU Clearance

    New Delhi, February 23 Drug maker Lupin announced on Monday that it has received approval from the European Commission for its biosimilar for the treatment of various eye conditions.The company has received approval for Ranluspec (ranibizumab), following the recent positive opinion from the...
    • Priyanka
    • News
    • age-related macular degeneration biosimilar bse choroidal neovascularization diabetic macular edema european commission eye conditions germany lupin macular edema pharmaceuticals proliferative diabetic retinopathy ranibizumab sandoz thierry volle
    • Replies: 0
    • Forum: Business
  2. A

    Zydus Launches Biosimilar for Diabetes-Related Visual Impairment

    New Delhi, February 19 Zydus Lifesciences announced on Thursday that it has launched its first biosimilar, developed indigenously, for the treatment of visual impairment.Anyra, the country's first biosimilar of Aflibercept 2 mg, is indicated for the treatment of visual impairment caused by...
    • Aditya
    • News
    • aflibercept anyra bayer biologics biosimilar diabetes drug development gujarat healthcare india ophthalmic care pharmaceuticals regeneron pharmaceuticals visual impairment zydus lifesciences
    • Replies: 0
    • Forum: Business
  3. D

    Supreme Court Defers Restraint on Zydus's Cancer Drug Biosimilar

    New Delhi, February 11 The Supreme Court on Wednesday refused to restrain Zydus Lifesciences from selling its affordable, generic biosimilar of Nivolumab, a life-saving cancer drug registered by Bristol Myers Squibb (BMS).A bench of Chief Justice Surya Kant and Justice Joymalya Bagchi was...
    • Devansh
    • News
    • biosimilar bristol myers squibb cancer drug delhi high court generic medicine nivolumab patent infringement zydus lifesciences
    • Replies: 0
    • Forum: National
Back
Top